ViiV Healthcare

HIV Pipeline Prospects Getting HealthierThere is no cure for HIV, but with proper medical treatment, the disease can be controlled.
Brand-name patent losses raise pharma cost concernsA number of traditional brand-name pharmaceuticals have lost, or will lose, patent protection this year. What does this mean over the longer-term for controlling costs?
Single-tablet HIV drug approved by FDAFDA has approved abacavir 600 mg, dolutegravir 50 mg (Tivicay) and lamivudine 300 mg (Triumeq, ViiV Healthcare) as as a first-line therapy to treat HIV.
FDA drug approvals-August 2014FDA actions in brief, complete response, fast-track designation, priority review, orphan drug designations, first-time generic approval